Related Experiment Videos
The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction
1Merck & Co., Inc., Whitehouse Station, New Jersey, USA. cook_john@merck.com
Insights
Enalapril significantly reduced mortality and heart failure hospitalizations in hypertensive patients with left ventricular dysfunction. This angiotensin-converting enzyme (ACE) inhibitor therapy proved cost-effective, offering clinical benefits and improved survival.
Area of Science:
- Cardiology
- Pharmacoeconomics
Background:
- Left ventricular dysfunction and hypertension are significant risk factors for cardiovascular events.
- Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs used to treat hypertension and heart failure.
Purpose of the Study:
- To evaluate the effect of enalapril on survival, resource utilization, and cost of care in hypertensive patients with left ventricular dysfunction.
- To determine the cost-effectiveness of enalapril therapy in this patient subgroup.
Main Methods:
- Retrospective analysis of 1917 hypertensive patients from the Studies of Left Ventricular Dysfunction (SOLVD) cohort.
- Comparison of outcomes between patients treated with enalapril and those not receiving the drug.
Main Results:
- Enalapril therapy was associated with a significant reduction in mortality (RR=0.819, P=.03) and risk of first hospitalization for heart failure (37% reduction).
- Treatment led to an average of 32 fewer hospitalizations per 100 patients and estimated savings of $1656 per patient during the trial.
- Evaluation indicated enalapril was a cost-effective strategy, with significant clinical benefits and improved survival.
Conclusions:
- Enalapril provides significant clinical benefits and is a cost-effective treatment for hypertensive patients with left ventricular dysfunction.
- ACE inhibitors should be considered first-line therapy for this patient population due to their favorable clinical and economic profiles.
Abstract:
This study examined the effect of enalapril on survival, resource use, and cost of care in patients with left ventricular dysfunction and hypertension using a retrospective analysis of patients who participated in the Studies of Left Ventricular Dysfunction (SOLVD). Among the 6797 SOLVD participants, 1917 patients had either elevated systolic (> or = 140 mm Hg) or diastolic (> or = 90 mm Hg) blood pressure. Therapy with enalapril was associated with a significant relative risk reduction for mortality (RR = 0.819, 95% CI: 0.68 to 0.98; P = .03). This resulted in a gain of 0.11 years (95% CI: 0.00 to 0.20 years) of survival during the average 2.8 year follow-up for this subgroup and was projected to result in a gain of 2.14 years (95% CI: 0.05 to 4.21 years) during the patient's lifetime. Enalapril significantly reduced the risk of first hospitalization for heart failure by 37%. For all types of hospitalizations, there was an average reduction of 32 hospitalizations per 100 patients treated with enalapril during the trial period (95% CI: 11.8 to 52.2 hospitalizations avoided per 100 patients), resulting in an estimated net savings of $1656 per patient during the trial period (95% CI: increased cost of $191 to savings of $3502). Although the projected lifetime net savings of $1456 was not significant (95% CI: increased cost of $9243 to saving of $12,527), evaluation of the cost per life year saved indicated that enalapril represented a cost-effective strategy. The estimated clinical benefit of enalapril among the hypertensive subgroup in SOLVD supports the recommendation that angiotensin converting enzyme (ACE) inhibitors should be considered as first line pharmacologic therapy for hypertensive patients with left ventricular dysfunction. From both the clinical and economic viewpoints, ACE inhibitors provide important clinical benefits and are cost-effective.